{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T08:32:20Z","timestamp":1779006740738,"version":"3.51.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ustekinumab (UST) is commonly used to treat Crohn\u2019s disease and ulcerative colitis. However, some patients may experience diminishing response or require increased dosage. Intravenous (IV) UST maintenance is explored as a solution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We sought to evaluate IV UST maintenance effectiveness and safety in inflammatory bowel disease patients with partial or lost subcutaneous UST response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multicenter retrospective study of inflammatory bowel disease patients on IV UST maintenance. Clinical response and remission at weeks 12 and 52, defined as Harvey-Bradshaw Index \u22644 for Crohn\u2019s disease or partial Mayo score \u22642 for ulcerative colitis. Objective markers reduction (fecal calprotectin, C-reactive protein), UST trough levels pre- and post-IV maintenance, and adverse events were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 59 patients were included. Clinical remission at weeks 12 and 52 achieved by 47.5% and 64.3% respectively. 96.6% continued IV UST at follow-up. UST serum levels quadrupled. No adverse events reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>IV UST maintenance effectively sustained remission in most patients at 52 weeks.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae152","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T02:56:09Z","timestamp":1722480969000},"page":"1003-1009","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing"],"prefix":"10.1093","volume":"31","author":[{"given":"Federico","family":"Arg\u00fcelles-Arias","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Virgen Macarena University Hospital , Seville ,","place":["Spain"]},{"name":"Department of Medicine, University of Seville , Seville ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F Javier","family":"Rodriguez Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen de la Victoria University Hospital , M\u00e1laga ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Gonz\u00e1lez Antu\u00f1a","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen Macarena University Hospital , Seville ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Castro Laria","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen Macarena University Hospital , Seville ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Guti\u00e9rrez Martinez","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen de la Victoria University Hospital , M\u00e1laga ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Alca\u00edn Martinez","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen de la Victoria University Hospital , M\u00e1laga ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Maldonado P\u00e9rez","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen Macarena University Hospital , Seville ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Camargo Camero","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen de la Victoria University Hospital , M\u00e1laga ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Victor","family":"Martos Van Dussen","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen de la Victoria University Hospital , M\u00e1laga ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Fern\u00e1ndez Casta\u00f1er","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen de la Victoria University Hospital , M\u00e1laga ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2142-5142","authenticated-orcid":false,"given":"Teresa","family":"Vald\u00e9s Delgado","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Virgen Macarena University Hospital , Seville ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"13","key":"2025041105234811500_CIT0001","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"issue":"20","key":"2025041105234811500_CIT0002","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"issue":"3","key":"2025041105234811500_CIT0003","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the Im-Uniti trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"2025041105234811500_CIT0004","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1093\/ibd\/izab019","article-title":"Ustekinumab dose optimization in Crohn disease: one size does not fit all","volume":"27","author":"Dalal","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2025041105234811500_CIT0005","doi-asserted-by":"publisher","first-page":"686","DOI":"10.17235\/reed.2023.9402\/2022","article-title":"Effectiveness and safety of ustekinumab dose escalation in Crohn\u2019s disease: a multicenter observational study","volume":"115","author":"Olmedo Mart\u00edn","year":"2023","journal-title":"Rev Esp Enferm Dig."},{"issue":"7624","key":"2025041105234811500_CIT0006","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"2025041105234811500_CIT0007","doi-asserted-by":"publisher","first-page":"17562848231191670","DOI":"10.1177\/17562848231191670","article-title":"Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing","volume":"16","author":"Arg\u00fcelles-Arias","year":"2023","journal-title":"Therap Adv Gastroenterol."},{"issue":"9","key":"2025041105234811500_CIT0008","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.dld.2019.05.002","article-title":"Effectiveness and safety of Ustekinumab for Crohn\u2019s disease; systematic review and pooled analysis of real-world evidence","volume":"51","author":"Engel","year":"2019","journal-title":"Dig Liver Dis."},{"issue":"7","key":"2025041105234811500_CIT0009","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/apt.16802","article-title":"Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases","volume":"55","author":"Yang","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"12","key":"2025041105234811500_CIT0010","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","article-title":"Effectiveness of reinduction and\/or dose escalation of ustekinumab in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"20","author":"Meserve","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2025041105234811500_CIT0011","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/apt.15784","article-title":"Effectiveness of ustekinumab dose escalation in Crohn\u2019s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy","volume":"52","author":"Kopylov","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2025041105234811500_CIT0012","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jcag\/gwac017","article-title":"Efficacy of intravenous ustekinumab reinduction in patients with Crohn\u2019s disease with a loss of response","volume":"5","author":"Heron","year":"2022","journal-title":"J Can Assoc Gastroenterol.."},{"issue":"10","key":"2025041105234811500_CIT0013","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/ecco-jcc\/jjac067","article-title":"Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis","volume":"16","author":"Alsoud","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025041105234811500_CIT0014","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s10620-023-07822-7","article-title":"Ustekinumab trough concentrations are associated with biochemical outcomes in patients with Crohn\u2019s disease","volume":"68","author":"Straatmijer","year":"2023","journal-title":"Dig Dis Sci."},{"issue":"3","key":"2025041105234811500_CIT0015","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s13318-023-00824-w","article-title":"Relationship between serum ustekinumab trough concentration and clinical and biochemical disease activity: a real-world study in adult patients with Crohn\u2019s disease","volume":"48","author":"Nguyen","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae152\/58703068\/izae152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/1003\/58703068\/izae152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/1003\/58703068\/izae152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:23:51Z","timestamp":1744349031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/4\/1003\/7724741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae152","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,7,31]]}}}